These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15193461)

  • 21. Hormone therapy and breast cancer risk.
    Foidart JM; Desreux J; Pintiaux A; Gompel A
    Climacteric; 2007 Oct; 10 Suppl 2():54-61. PubMed ID: 17882674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.
    Skouby SO; Al-Azzawi F; Barlow D; Calaf-Alsina Erdogan Ertüngealp J; Gompel A; Graziottin A; Hudita D; Pines A; Rozenberg S; Samsioe G; Stevenson JC;
    Maturitas; 2005 May; 51(1):8-14. PubMed ID: 15883103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA
    Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer risk with postmenopausal hormonal treatment.
    Collins JA; Blake JM; Crosignani PG
    Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Women's awareness and knowledge of hormone therapy post-Women's Health Initiative.
    Rigby AJ; Ma J; Stafford RS
    Menopause; 2007; 14(5):853-8. PubMed ID: 17429334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacology and differential cognitive efficacy of estrogen preparations.
    Gleason CE; Carlsson CM; Johnson S; Atwood C; Asthana S
    Ann N Y Acad Sci; 2005 Jun; 1052():93-115. PubMed ID: 16024754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormone replacement therapy post Women's Health Initiative study: where do we stand?
    Calleja-Agius J; Brincat MP
    Curr Opin Obstet Gynecol; 2008 Dec; 20(6):513-8. PubMed ID: 18989125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Women's attitudes to hormone replacement therapy in the aftermath of the Women's Health Initiative study.
    Sveinsdóttir H; Olafsson RF
    J Adv Nurs; 2006 Jun; 54(5):572-84. PubMed ID: 16722955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postmenopausal hormone therapy before and after the women's health initiative study: what consequences?
    Mikkola TS; Clarkson TB; Notelovitz M
    Ann Med; 2004; 36(6):402-13. PubMed ID: 15513292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beyond menopause. Life after estrogen.
    Mayo Clin Health Lett; 2005 Feb; Suppl():1-8. PubMed ID: 15732174
    [No Abstract]   [Full Text] [Related]  

  • 31. The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone therapy.
    Genazzani AR; Schneider HP; Panay N; Nijland EA
    Gynecol Endocrinol; 2006 Jul; 22(7):369-75. PubMed ID: 16864146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is there a place for postmenopausal hormone therapy use in women with lupus?
    Gompel A; Piette JC
    Panminerva Med; 2008 Sep; 50(3):247-54. PubMed ID: 18927529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
    Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interactions between melatonin and estrogen may regulate cerebrovascular function in women: clinical implications for the effective use of HRT during menopause and aging.
    Harrod CG; Bendok BR; Hunt Batjer H
    Med Hypotheses; 2005; 64(4):725-35. PubMed ID: 15694689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial.
    Maki PM; Gast MJ; Vieweg AJ; Burriss SW; Yaffe K
    Neurology; 2007 Sep; 69(13):1322-30. PubMed ID: 17893293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits and risks of long-term low-dose oral continuous combined hormone therapy.
    van de Weijer PH; Mattsson LA; Ylikorkala O
    Maturitas; 2007 Mar; 56(3):231-48. PubMed ID: 17034966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Harnessing hormonal signaling for cardioprotection.
    Ballard VL; Edelberg JM
    Sci Aging Knowledge Environ; 2005 Dec; 2005(51):re6. PubMed ID: 16371658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease.
    American College of Obstetricians and Gynecologists Committee on Gynecologic Practice
    Obstet Gynecol; 2008 Nov; 112(5):1189-92. PubMed ID: 18978127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postmenopausal hormone therapy: new questions and the case for new clinical trials.
    Manson JE; Bassuk SS; Harman SM; Brinton EA; Cedars MI; Lobo R; Merriam GR; Miller VM; Naftolin F; Santoro N
    Menopause; 2006; 13(1):139-47. PubMed ID: 16607110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system?
    Rosano GM; Vitale C; Fini M
    Ann N Y Acad Sci; 2006 Dec; 1092():341-8. PubMed ID: 17308159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.